Chronic Kidney Disease
Conditions
Keywords
chronic kidney disease starting dialysis, cardiovascular risk, bone mineral metabolism markers
Brief summary
To evaluate the relationships between bone mineral markers levels at dialysis start and vascular calcification progression during a 2 year follow up
Interventions
BIOLOGICALPlasma osteoprotegerin level
dosage of plasma osteoprotegerin
BIOLOGICALPlasma fibroblast growth factor 23 level
dosage of plasma fibroblast growth factor 23
PROCEDUREVascular calcification score
measurement of vascular calcification score by X-ray of the lateral abdominal aorta
Sponsors
University Hospital, Montpellier
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Patient who has signed the written consent form * Patient with chronic renal failure starting dialysis therapy
Exclusion criteria
* Pregnancy * Patient with chronic renal failure not yet on dialysis therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression of vascular calcifications during a 2 year follow up according to plasma osteoprotegerin level at inclusion | 2 years after inclusion | osteoprotegerin will be measured in picomol/L; vascular calcifications will be measured at inclusion and after the 2 year follow up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression of vascular calcifications during a 2 year follow up according to plasma fibroblast growth factor 23 level at inclusion | 2 years after inclusion | fibroblast growth factor 23 will be measured in RU/milliliter; vascular calcifications will be measured at inclusion and after the 2 year follow up |
| Occurence of cardiovascular events during a 2 year follow up | 2 years after inclusion | — |
Countries
France
Contacts
Primary ContactJean-Paul Cristol, Prof
Backup ContactMarion Morena, PhD
Outcome results
None listed